On4 Communications Inc (ONCI): $ONCI bid is back now pic.twitter.com/mm...

Play Episode

6min

Proactive - Interviews for investors

Zynex Medical champions noninvasive, non-addictive pain management with NexWave

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

North Bay Resources identifies potential of major gold deposit at Fran Project

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to announce the discovery of a significant mass tonnage gold deposit at the Fran Gold Project, following an extensive review of prior exploration work. This includes data from diamond drilling campaigns between 2001 and 2018, as well as geochemical, geophysical, and 3D modeling analyses. Key findings reveal that past drilling—totaling over 18,000 meters—intersected large gold-bearing zones, with notable intercepts of up to 149 meters (489 feet) at 0.95 grams per tonne (g/t) gold. The identified deposit spans over 1,000m x 100m x 300m within a known strike length of 1,700m, indicating an exploration potential of 79.5 million tonnes, with an average grade of 0.8 g/t gold, translating to a potential 2 million ounces. Lazerson stated that there is now sufficient data to proceed with a NI 43-101 Compliant Mineral Resource Estimate. Historically, exploration at Fran focused on high-grade vein targets for underground mining, leaving the bulk tonnage potential largely unexplored. However, North Bay's latest review has shifted its strategy, incorporating both high-grade surface material for processing at its Bishop Gold Mill and ongoing evaluation of the mass tonnage gold deposit for future large-scale mining opportunities. This dual approach could significantly enhance North Bay’s production capacity, reinforcing its commitment to maximizing the Fran Gold Project’s full economic potential #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #MiningUpdates ---#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive - Interviews for investors

Oriole Resources wraps up pivotal 2024, targets major gold milestones in 2025

Oriole Resources PLC (AIM:ORR) CEO Martin Rosser and CFO Bob Smeeton take Proactive's Stephen Gunnion through the company’s latest full-year results and upcoming milestones across its key exploration projects. Rosser highlighted a pivotal year for the company’s Bibemi and Mbe gold projects in Cameroon. At Bibemi, a recently completed phase five drilling campaign is feeding into a revised Mineral Resource Estimate (MRE), expected this quarter. “We believe there's very good potential to not just increase the amount of gold, but also improve the category of the resource,” said Rosser. The company is also advancing an exploitation license application for the project. At Mbe, maiden drilling continues, following trenching results that indicated strong mineralisation. “We think Mbe South has significant potential to host a substantial gold deposit,” Rosser added. Smeeton detailed a £2 million reduction in operating loss and financial support from BCM International. “Since year-end, BCM have given us $1.1 million, largely replenishing CapEx,” Smeeton noted. He also confirmed progress on a joint venture agreement with Managem at the Senala project in Senegal. Rosser pointed to potential sector-wide revaluations driven by high gold prices and possible M&A activity. “Oriole’s shares are significantly undervalued,” he said. For more updates from Oriole Resources and other mining sector interviews, give this video a like, subscribe to Proactive’s YouTube channel, and enable notifications so you don’t miss future content. #OrioleResources #GoldExploration #CameroonMining #MbeProject #BibemiGold #JuniorMiners #MiningInvestment #MineralResourceEstimate #GoldPrice #MiningFinance #ProactiveInvestors #ManagemJV #SenalaProject #CameroonGold #ExplorationDrilling

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Followers	335
Posts	24104
Boards Moderated	1
Alias Born	12/10/2010

Volume:	1,000,000
Day Range:	0.0001 - 0.0001
Bid:	0.0001
Ask:	0.0001
Last Trade Time:	11:01:18 AM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ONCI Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free